Melanoma treatment depends heavily on how deep the tumor has grown and whether it has spread. For early-stage melanoma caught before it reaches the lymph nodes, surgery alone is often curative, with a five-year survival rate of nearly 100%. When melanoma has spread regionally or to distant organs, treatment combines surgery with immunotherapy, targeted therapy, or radiation to control the disease and extend survival.
How Staging Shapes Your Treatment Plan
Before treatment begins, your care team determines how advanced the melanoma is. The main measurement is tumor thickness in millimeters, assessed under a microscope after a biopsy. Tumors 1 mm or thinner are classified as T1, those between 1.01 and 2 mm as T2, between 2.01 and 4 mm as T3, and anything thicker than 4 mm as T4. Whether the surface of the tumor is ulcerated (broken through the skin) also matters, as ulceration bumps a tumor into a higher-risk category even if it’s relatively thin.
These thickness categories, combined with whether cancer has reached the lymph nodes or other organs, determine your overall stage (0 through IV) and directly dictate which treatments are recommended.
Surgery for Early-Stage Melanoma
Surgery is the primary treatment for melanoma that hasn’t spread beyond the skin, and for most people with early-stage disease, it’s the only treatment needed. The procedure involves cutting out the melanoma along with a margin of healthy skin around it to ensure no cancer cells remain at the edges.
The width of that margin depends on tumor thickness:
- Melanoma in situ (Stage 0): 0.5 to 1 cm margin. The cancer is entirely within the top layer of skin.
- T1 melanoma (up to 1 mm thick): 1 cm margin.
- T2 melanoma (1.01 to 2 mm thick): 1 to 2 cm margin.
For thicker tumors, margins widen further. Your surgeon may also perform a sentinel lymph node biopsy, removing one or two nearby lymph nodes to check whether cancer cells have started to migrate. If those nodes are clear, the cancer is considered localized and your prognosis is excellent.
Adjuvant Therapy After Surgery
Even after a melanoma is fully removed, some patients face a meaningful risk of recurrence. People with stage IIB or IIC melanoma (thicker tumors or ulcerated tumors) carry a recurrence risk similar to patients whose cancer has already reached the lymph nodes, despite having node-negative disease. For these patients, adjuvant immunotherapy after surgery can reduce the chance of the cancer coming back.
The immunotherapy drug pembrolizumab received FDA approval for this purpose after a large international trial showed it improved recurrence-free survival in patients with resected high-risk stage II melanoma. Treatment typically involves infusions given every few weeks for up to a year. The goal isn’t to treat visible cancer, since surgery already removed it, but to train the immune system to hunt down any stray cells that might seed a future recurrence.
Immunotherapy for Advanced Melanoma
Immunotherapy has transformed outcomes for people with melanoma that has spread to lymph nodes or distant organs. These drugs work by releasing the brakes on your immune system so it can recognize and attack cancer cells it was previously ignoring.
The most commonly used drugs are checkpoint inhibitors, which block proteins on immune cells that normally keep them in check. Nivolumab blocks a protein called PD-1, and a newer combination called Opdualag pairs nivolumab with relatlimab, which blocks a second immune checkpoint called LAG-3. By targeting two checkpoints at once, the combination gives the immune system a stronger push against the tumor.
These treatments are given as intravenous infusions, typically every two to four weeks. They can produce durable responses in some patients, meaning the cancer stays controlled for years. However, they also carry a risk of immune-related side effects, which happen when the revved-up immune system attacks healthy tissues. In real-world data from melanoma patients receiving adjuvant PD-1 inhibitors, about 15% experienced severe side effects requiring treatment interruption or hospitalization. A small fraction (roughly 0.6%) died from treatment toxicity. Common immune-related problems include inflammation of the skin, gut, liver, lungs, or thyroid gland. Most of these are manageable when caught early, which is why your care team monitors bloodwork and symptoms closely during treatment.
Targeted Therapy for BRAF-Positive Melanoma
About half of all melanomas carry a mutation in the BRAF gene, which acts like a stuck gas pedal telling cancer cells to grow uncontrollably. If your tumor tests positive for a BRAF mutation, you may be a candidate for targeted therapy: pills that specifically disable the signaling pathway driving your cancer’s growth.
The standard approach combines two types of drugs. A BRAF inhibitor (such as dabrafenib, vemurafenib, or encorafenib) directly blocks the mutant protein, while a MEK inhibitor (such as trametinib, cobimetinib, or binimetinib) blocks a closely connected protein in the same pathway. Using both together works better than either alone and helps prevent the cancer from quickly developing resistance. These combinations can shrink tumors or slow their growth substantially in many patients.
Targeted therapy is taken as daily oral medication rather than infusions. Side effects differ from immunotherapy and can include fever, joint pain, skin rashes, and sensitivity to sunlight. Your oncologist will choose between immunotherapy and targeted therapy (or sequence them) based on how fast the cancer is progressing, where it has spread, and your overall health.
Radiation Therapy
Radiation is not a frontline treatment for melanoma the way it is for some other cancers, but it plays an important role in specific situations. The most common use is treating melanoma that has spread to the brain, where surgery may not be feasible or where tumors are too numerous to remove individually.
Stereotactic radiosurgery delivers a highly focused beam of radiation to brain metastases with millimeter precision, sparing surrounding brain tissue. For patients with multiple brain lesions, whole-brain radiation may be used instead. The primary goal is to relieve neurological symptoms caused by the tumors and surrounding swelling, and to prevent further decline. Radiation can also be directed at other areas where melanoma is causing pain or threatening critical structures.
TIL Therapy: A Newer Option
For patients whose advanced melanoma has progressed through both immunotherapy and targeted therapy, a newer treatment called TIL (tumor-infiltrating lymphocyte) therapy offers another option. The FDA approved the first TIL therapy, lifileucel, for this situation in 2024.
The process is intensive. Surgeons remove a piece of your tumor, and the immune cells found inside it are sent to a manufacturing facility where they’re multiplied into billions of cancer-fighting cells over several weeks. Before the cells are infused back into your body, you receive several rounds of high-dose chemotherapy to deplete your existing immune cells and make room for the new ones. After the infusion, you receive additional doses of a growth factor to help the transplanted cells thrive.
TIL therapy requires normal heart and lung function because the preparatory chemotherapy and post-infusion drugs put significant stress on the body. It involves a hospital stay and a recovery period. This treatment is reserved for people who have run out of other effective options, but it represents a genuinely new mechanism: using your own tumor-specific immune cells, supercharged in a lab, to fight back.
Survival Rates by Stage
Melanoma outcomes vary dramatically depending on when the cancer is caught. SEER data covering 2016 through 2022 shows the following five-year relative survival rates:
- Localized melanoma (confined to the skin): 100%
- Regional spread (cancer in nearby lymph nodes): 76%
- Distant metastasis (cancer in other organs): 34%
The distant-stage number, while sobering, has improved considerably over the past decade thanks to immunotherapy and targeted therapy. Before these treatments became available, the five-year survival rate for metastatic melanoma was in the single digits. The 34% figure reflects a real and ongoing shift in what’s possible for people with advanced disease. Early detection remains the single most powerful factor in melanoma outcomes, which is why skin checks and prompt evaluation of changing moles matter so much.